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Background
The CentriMag mechanical support device (Levitronix
LLC, Waltham, USA) is intended for short-term para-
corporeal circulatory support in patients in refractory
cardiogenic shock. The paper presents our experience
with this device allowing urgent initiation of biventricu-
lar circulatory support.
Methods
From December 2009 through October 2012, the Cen-
triMag device was implanted in 11 patients (2 women)
transferred to our institution with refractory biventricu-
lar end-stage heart failure and multisystem organ failure.
The mean age of our patients was 46.5 ± 12.0 years
(range, 20–64 years). The basic cardiac disease was
dilated cardiomyopathy (7 patients), myocarditis
(2 patients) and coronary artery disease (2 patients).
Results
The mean ventricular support time was 26.9 ± 16.5 days
(range, 11 –71 days). In six patients (55%), mechanical
support was completed with heart transplantation. Recov-
ery of heart function occurred in two (18%) patients.
Three (27%) patients died while on the support device.
The 30-day and one-year survival rates were 64%
(7 patients) and 55% (6 patients), respectively. The mean
time from support device implantation to putting the
patient on the waiting list was 13.4 ± 20.5 days (range, 0–
57 days) depending on recovery of organ (including the
CNS) function. The mean waiting time was 14.6 ±
11.3 days (range, 3–35 days). The three-month and one-
year survival rates after heart transplantation were 83%
and 67% (4 of 6 patients), respectively.
Conclusion
The installation of the Levitronix CentriMag device in
our center resulted in a marked improvement of an
otherwise grim prognosis of patients whose anticipated
survival rates, unless undergoing urgent mechanical
cardiac support implantation would be in the order of
hours, or several days at most.
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